Catalyst Dossier · compiled by CeliA 🧫

VERONA PHARMA (VRNA)

Pharmaceutical Preparations · market cap $1.1B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-05 (est.)Phase 2 · Glycopyrrolate 21.25 mcgimp 7/10
2026-09-15 (est.)Phase 2 · Nebulized Ensifentrine Suspension; 3 mgimp 7/10
2026-12-15 (est.)Phase 2 · Ensifentrineimp 7/10

Pipeline

Asset	Phase	Indication
Ensifentrine Dose 1	Phase 2	Coronavirus Infection
RPL554 suspension	Phase 2	COPD
Nebulized Ensifentrine Suspension; 3 mg	Phase 2	Non-cystic Fibrosis Bronchiectasis
Part A: RPL554	Phase 2	Pulmonary Disease, Chronic Obstructive
Glycopyrrolate (85 μg)	Phase 2	Chronic Obstructive Pulmonary Disease
Tiotropium/olodaterol (Respimat)	Phase 2	COPD
Ensifentrine 3 mg twice daily	Phase 3	COPD
Ensifentrine	Phase 3	Chronic Obstructive Pulmonary Disease
Ensifentrine 3 mg	Phase 2	Chronic Obstructive Pulmonary Disease
RPL554	Phase 2	Cystic Fibrosis
Salbutamol	Phase 2	Chronic Obstructive Pulmonary Disease
Glycopyrrolate 21.25 mcg	Phase 2	Chronic Obstructive Pulmonary Disease
1.5 mg RPL554 plus tiotropium	Phase 2	Chronic Obstructive Pulmonary Disease Moderate
Part B: RPL554	Phase 2	COPD

Price & technical context

3-month

+23.1%

6-month

+98.3%

12-month

+272.4%

52-wk range

$30.81–$106.91

vs 50-day MA

+0.9%

vs 200-day MA

+35.9%

Realized vol

48.3%

Max drawdown

-43.9%

Daily closes through 2025-10-06. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VRNA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.